Growth in revenue and cash is strong after four months of trading. Focusrite continues to build on its leadership positions in international markets, and to benefit from its c 85% non-UK market exposure. Further growth in cash is also encouraging as it suggests good profit conversion despite expected cost increases. If these independent growth trends continue to the half-year, we would see upside risk to our forecasts.
10 Jan 2018
Focusrite - Music therapy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Focusrite - Music therapy
Focusrite PLC (TUNE:LON) | 335 16.8 1.5% | Mkt Cap: 198.4m
- Published:
10 Jan 2018 -
Author:
Paul Hickman -
Pages:
3
Growth in revenue and cash is strong after four months of trading. Focusrite continues to build on its leadership positions in international markets, and to benefit from its c 85% non-UK market exposure. Further growth in cash is also encouraging as it suggests good profit conversion despite expected cost increases. If these independent growth trends continue to the half-year, we would see upside risk to our forecasts.